InVasc Therapeutics


N.C. drug company’s first deal delivers key ingredient for kidney drug

Drug reformulation company BioLink Life Sciences has reached a licensing deal with an Atlanta firm planning to incorporate the North Carolina company’s research into its lead kidney disease drug candidate. InVasc Therapeutics‘ compound, called INV-144, is designed to slow the progression of chronic kidney disease, a condition affecting approximately 36 million patients in the United […]